Cell Death Dis:lncRNA HOXA-AS2 promotes the development of AML by binding EZH2 and inhibiting LATS2

Acute myeloid leukemia (AML) is the most common malignant tumor of the blood system in the world, and its two main characteristics are uncontrolled malignant proliferation and blocked differentiation, accounting for about 30% of leukemia-related deaths.
with the development of science and technology, the treatment of leukemia has made great progress, but the cure for the disease has not been solved, its five-year survival rate is only 25%.
AML patients have improved significantly since their treatment, many patients still have less than ideal prognostics.
increasing number of studies have shown that long non-coded RNA (lncRNA) plays a vital role in physiological and pathological development.
and has increasingly become biomarkers for tumor diagnosis, treatment, or prognosis, including AML.
previous studies have shown that lncRNA HOXA-AS2 plays an important role as a carcinogen in many tumors, but little is known about its role in AML.
the relative expression and clinical significance of HOXA-AS2 in AML tissue and cells is intended to explore the potential mechanism and function of HOXA-AS2 in AML.
researchers found that THE EXPRESSION levels of HOXA-AS2 increased in AML cell line and tissue, while over-expression levels of HOXA-AS2 were negatively associated with patient survival.
silence HOXA-AS2 inhibits the proliferation of AML cells and induces their differentiation, while over-expression OFSA-AS2 shows the opposite result.
addition, further mechanism studies have shown that hoxA-AS2 carcinogenicity is achieved primarily by binding to EZH2 and inhibiting the expression of LATS2.
the results of the study, which show that the expression of
knock-down HOXA-AS2 inhibits the occurrence of AML tumors, reveals the important role of HOXA-AS2 in AML, and suggests that HOXA-AS2 may be an effective therapeutic target for AML patients.
。